Chrysalin Phase III Data Fails To Crystallize Future Of Synthetic Peptide
This article was originally published in The Pink Sheet Daily
Executive Summary
OrthoLogic’s Chrysalin fails to meet its Phase III trial primary endpoint; a Phase IIb dose ranging study will determine the drug’s fate.